FACIT

What FACIT does

FACIT (Fight Against Cancer Innovation Trust) is a private commercialization venture firm established in 2014 by the Ontario Institute for Cancer Research (OICR) and headquartered at the MaRS Centre in Toronto, Ontario. The firm is structured as an independent business trust funded in part by the Government of Ontario through OICR, and operates as the commercialization arm of Ontario's cancer research ecosystem. Its core function is to bridge the $2-10M seed and early venture funding gap commonly faced by Ontario oncology start-ups, providing seed capital, company formation, executive management, intellectual property management, and strategic partnership facilitation to researchers and entrepreneurs originating from Ontario's academic institutions.

FACIT does not develop proprietary technology itself; instead it deploys capital and operational support through a continuum of vehicles including the Compass Rose Oncology Fund (pre-seed and seed), the Prospects Oncology Fund (early-stage Ontario First capital), and the WeSEED program (a joint initiative with OBIO supporting women-led start-ups). It runs the annual Falcons' Fortunes pitch competition (now in its 13th year) as a deal-sourcing and brand-building event. Portfolio companies span therapeutics (small molecules, biologics, antibody-drug conjugates, radiopharmaceuticals, oncolytic viral immunotherapies), medical technologies (imaging, diagnostics, surgical devices), and digital health solutions, including Turnstone Biologics, Fusion Pharmaceuticals, Propellon Therapeutics, Radiant Biotherapeutics, and Triphase Accelerator.

FACIT's revenue model is based on equity appreciation and exit-driven returns from portfolio companies, with proceeds reinvested into Ontario's oncology innovation pipeline rather than distributed. Notable outcomes include the acquisition of portfolio company Fusion Pharmaceuticals by AstraZeneca for up to US$2.4 billion, the 2019 Celgene partnership (US$40M upfront plus up to US$940M in milestones) facilitated for portfolio companies Propellon Therapeutics and Triphase Accelerator, and 11 documented exits in total. Since inception FACIT has attracted over US$1.7 billion in follow-on investment to its portfolio, created 20+ Ontario start-ups, and supported 17 first-in-human clinical studies.

Name

FACIT

Legal name

Fight Against Cancer Innovation Trust

Website

https://facit.ca

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

FACIT is a Toronto-based commercialization venture firm established by the Ontario Institute for Cancer Research that provides seed capital, company formation, and strategic commercialization support to Ontario-based oncology start-ups, managing the Compass Rose Oncology Fund and a portfolio of over 20 ventures.

Ownership category

akta.pro rank

Product category

Life Sciences Venture Capital

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Impact / ESG Venture Capital (FSANAAAG)

Keywords

• Oncology venture capital
• Seed-stage investment
• Biotech commercialization
• Life sciences funding
• Cancer innovation financing

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Investment Returns: FACIT generates returns through equity investments in portfolio companies, which appreciate in value as companies advance through clinical development, secure strategic partnerships, complete financing rounds, achieve exits through acquisitions or IPOs. FACIT reinvests proceeds from returns for future opportunities in Ontario innovations.
2. Portfolio Company Success: FACIT benefits from successful exits of portfolio companies. Notable exits include Fusion Pharmaceuticals (acquired by AstraZeneca for up to US$2.4B), Privacy Analytics (acquired by IQVIA/IMS Health), DVS Sciences (acquired by Fluidigm), and multiple strategic partnerships generating milestone payments.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

FACIT is a commercialization venture firm that provides seed-stage equity capital, strategic guidance, and commercialization resources to Ontario-based oncology start-ups. It manages investment funds (Compass Rose Oncology Fund, Prospects Oncology Fund) and entrepreneurship programs (WeSEED, Falcons' Fortunes) that bridge the $2-10M funding gap for early life science ventures, helping to form and scale companies developing cancer therapeutics, diagnostics, and medical technologies.

Product overview

FACIT is an award-winning commercialization venture firm that operates as a single unified offering rather than a platform-plus-modules architecture. Rather than selling products or services directly, FACIT manages a continuum of investment funds (Compass Rose Oncology Fund, Prospects Oncology Fund) and entrepreneurial support programs (WeSEED, Falcons' Fortunes) that together provide seed capital, company-building expertise, and strategic networks to Ontario-based oncology start-ups. The Compass Rose Oncology Fund targets the $2-10M seed funding gap for early-stage life science ventures, while the Prospects Fund fuels emerging innovations. The WeSEED program specifically supports women-led companies in partnership with OBIO®, and Falcons' Fortunes is the annual pitch competition that surfaces and rewards breakthrough cancer innovations. FACIT blends industry experience, capital, and the clinician-scientist network of its strategic partner OICR to accelerate oncology innovation from research to market.

Differentiator

Problem solved

Functional benefit

Products and services

• Compass Rose Oncology Fund A seed-stage investment fund that bridges the $2-10M funding gap commonly faced by early life science start-ups in Ontario's oncology sector, investing in pre-seed and seed stage ventures to support company formation and early development. Targeted at Ontario-based oncology entrepreneurs and researchers.
• Prospects Oncology Fund An early-stage fund providing Ontario First capital to promising cancer innovations, helping start-ups reach critical value inflection points and establish roots in the province. Aimed at oncology entrepreneurs seeking initial funding and validation.
• WeSEED Program Women's Synergistic Entrepreneurship and Economic Development program in partnership with OBIO that provides business training, advisory resources, strategic networks, and venture funding to women-led oncology companies in Ontario's health and biotech sector.
• Falcons' Fortunes Pitch Competition FACIT's premier annual pitch competition and networking event bringing together ecosystem partners and entrepreneurs from across Ontario to compete for the $100,000 Ernsting Entrepreneurship award for breakthrough cancer innovations. Targets early-stage oncology ventures seeking seed funding.

Quantifiable outcome

• Over $1.7 billion in follow-on investment attracted to Ontario oncology start-ups
• +4 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Ten partnerships are on record, tiered supporting, core and major.

• University of Toronto's PRiME initiativesupportingStrategic or Co-development Partner · 31 March 2026OBIO and FACIT's joint WeSEED program partners with University of Toronto's PRiME initiative and BioLabs - University of Toronto to launch an Entrepreneurship Training Program for Women in STEM.
• OBIO® (Ontario Bioscience Innovation Organization)coreStrategic or Co-development Partner · 6 March 2025FACIT and OBIO announced the inaugural WeSEED (Women's Synergistic Entrepreneurship and Economic Development) cohort - a joint seed capital and commercialization program supporting women-led start-ups in healthcare and health tech with funding, business training, advisory resources, and strategic networks.
• Ontario Centre of Innovation (OCI)majorStrategic or Co-development Partner · 8 March 2024FACIT joined OCI's strategic network through an MOU bringing together 11 key strategic commercialization partners in Ontario's life sciences ecosystem to expand support for health innovators and start-ups across the province.
• Celgene Corporation (now Bristol-Myers Squibb)coreStrategic or Co-development Partner · 29 January 2019Celgene partnered with Triphase Accelerator (majority shareholder FACIT) and Propellon Therapeutics for first-in-class WDR5 inhibitors for blood cancers. Deal included US$40M upfront and up to US$940M in contingent milestones - the largest transaction to date for a Canadian-discovered preclinical asset.
• AbbVie Inc.coreStrategic or Co-development Partner · 10 October 2017AbbVie entered into a research, option and license agreement with Turnstone Biologics (a FACIT co-founded company) for up to three of Turnstone's next-generation oncolytic viral immunotherapies. This partnership represents a transformative collaboration for Ontario-developed cancer therapies.
• Ontario Institute for Cancer Research (OICR)coreStrategic or Co-development PartnerFACIT was established by OICR to support commercialization, technology transfer, and development activities. OICR conducts world-class cancer research as a pan-provincial connector of oncology researchers, resources and cancer innovation development. Together, FACIT and OICR drive a shared vision to attract more R&D investment in Ontario and help the best oncology innovations reach the market and save lives.
• Ontario Regional BioTherapeutics Program (ORBiT)majorStrategic or Co-development PartnerOICR's ORBiT program supports Turnstone Biologics' clinical trials with financial support, working with multiple Ontario research institutions including CHEO, McMaster, and The Ottawa Hospital.
• McMaster UniversitysupportingStrategic or Co-development PartnerOne of the founding research institutions for Turnstone Biologics, along with CHEO, OICR, Ottawa Hospital Research Institute, and University of Ottawa. Dr. Brian Lichty from McMaster serves as Turnstone's CTO.
• Children's Hospital of Eastern Ontario (CHEO) Research InstitutesupportingStrategic or Co-development PartnerFounding research institution for Turnstone Biologics. Dr. David Stojdl from CHEO is one of Turnstone's founding scientists.
• Ottawa Hospital Research InstitutesupportingStrategic or Co-development PartnerFounding research institution for Turnstone Biologics. Dr. John Bell from The Ottawa Hospital is one of Turnstone's founding scientists and Senior Scientist.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Market position

Weaknesses4 records

Competitive moat5 records

Customer concentration

• Xx.com/FACITca
• LinkedInlinkedin.com/company/facit-commercialization-venture

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments30 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FACIT